Watch More Highlights
Lindsey M. Lyle, MS, PA-C, of the University of Colorado Anschutz Medical Campus, discusses phase III data from the PRINCE study, which showed that patients with paroxysmal nocturnal hemoglobinuria who were naive to complement-inhibitor treatment demonstrated meaningful hematologic and clinical improvements following 26 weeks of treatment with the monoclonal antibody pegcetacoplan (Abstract 606).